MX2024003952A - Combinación que comprende atogepant para tratar la migraña. - Google Patents
Combinación que comprende atogepant para tratar la migraña.Info
- Publication number
- MX2024003952A MX2024003952A MX2024003952A MX2024003952A MX2024003952A MX 2024003952 A MX2024003952 A MX 2024003952A MX 2024003952 A MX2024003952 A MX 2024003952A MX 2024003952 A MX2024003952 A MX 2024003952A MX 2024003952 A MX2024003952 A MX 2024003952A
- Authority
- MX
- Mexico
- Prior art keywords
- atogepant
- combination
- treating migraine
- migraine
- treating
- Prior art date
Links
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 title abstract 2
- 208000019695 Migraine disease Diseases 0.000 title abstract 2
- 229940070146 atogepant Drugs 0.000 title abstract 2
- 206010027599 migraine Diseases 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163261731P | 2021-09-27 | 2021-09-27 | |
| US202163261782P | 2021-09-28 | 2021-09-28 | |
| US202163261783P | 2021-09-28 | 2021-09-28 | |
| US202263336843P | 2022-04-29 | 2022-04-29 | |
| US202263395134P | 2022-08-04 | 2022-08-04 | |
| PCT/US2022/077061 WO2023049920A1 (en) | 2021-09-27 | 2022-09-27 | Combination comprising atogepant for treating migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003952A true MX2024003952A (es) | 2024-05-27 |
Family
ID=83899967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003952A MX2024003952A (es) | 2021-09-27 | 2022-09-27 | Combinación que comprende atogepant para tratar la migraña. |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US12350259B2 (enExample) |
| EP (1) | EP4408418A1 (enExample) |
| JP (1) | JP2024533756A (enExample) |
| AU (1) | AU2022353124A1 (enExample) |
| CA (1) | CA3234080A1 (enExample) |
| MX (1) | MX2024003952A (enExample) |
| WO (1) | WO2023049920A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10117836B2 (en) | 2014-02-05 | 2018-11-06 | Merck Sharp & Dohme Corp. | Tablet formulation for CGRP active compounds |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| MX2023001071A (es) | 2020-07-29 | 2023-05-12 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| JP2024533756A (ja) | 2021-09-27 | 2024-09-12 | アラガン ファーマスーティカルズ インターナショナル リミテッド | アトゲパントを含む片頭痛の併用療法 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5914129A (en) * | 1996-07-23 | 1999-06-22 | Mauskop; Alexander | Analgesic composition for treatment of migraine headaches |
| US6103260A (en) | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
| CA2479672A1 (en) | 2002-03-18 | 2003-10-02 | Roger K. Cady | Preemptive prophylaxis of migraine |
| DE10228326A1 (de) * | 2002-06-25 | 2004-01-22 | Heribert Dr.med. Bohlen | Verwendung von Macrolid- und/oder Tetracyclin-Verbindungen und/oder Gyrasehemmer enthaltenden Präparationen zur Prophylaxe und therapeutischen Behandlung von Migräne und Migräne-verwandten Erkrankungen |
| US20040076668A1 (en) | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
| EP1606286B1 (en) | 2003-03-14 | 2011-05-11 | Merck Sharp & Dohme Corp. | Benodiazepine spirohydantoin cgrp receptor antagonists |
| US7288559B2 (en) | 2003-03-14 | 2007-10-30 | Merck + Co, Inc. | Carboxamide spirohydantoin CGRP receptor antagonists |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| CA2543458A1 (en) | 2003-10-24 | 2005-05-12 | Josef Rettenmaier & Soehne Gmbh & Co., Kg | Process for co-spray drying agents with dry silicified mcc |
| US8003792B2 (en) | 2004-09-13 | 2011-08-23 | Merck Sharp & Dohme Corp. | Bicyclic anilide spirolactam CGRP receptor antagonists |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| DE102004063755A1 (de) | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
| EP1861399B1 (en) | 2005-03-14 | 2011-12-14 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
| CN101378731B (zh) | 2006-02-09 | 2014-03-05 | 默沙东公司 | Cetp抑制剂的聚合物制剂 |
| WO2007133491A1 (en) | 2006-05-09 | 2007-11-22 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
| CA2689217C (en) | 2007-06-05 | 2016-02-16 | Merck & Co., Inc. | Carboxamide heterocyclic cgrp receptor antagonists |
| NZ585347A (en) | 2007-10-18 | 2011-09-30 | Boehringer Ingelheim Int | Cgrp antagonists |
| EP2225237A2 (de) | 2007-11-22 | 2010-09-08 | Boehringer Ingelheim International GmbH | Organische verbindungen |
| JP2011511792A (ja) | 2008-02-05 | 2011-04-14 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｇｒｐ受容体アンタゴニストのプロドラッグ |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US20150023888A1 (en) | 2008-09-05 | 2015-01-22 | Map Pharmaceuticals, Inc. | Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine |
| WO2010114801A1 (en) | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| US8765763B2 (en) | 2009-06-05 | 2014-07-01 | Boehringer Ingelheim International Gmbh | Substituted piperazines as CGRP antagonists |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| WO2012064911A1 (en) | 2010-11-12 | 2012-05-18 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide indane cgrp receptor antagonists |
| TWI501968B (zh) | 2010-11-12 | 2015-10-01 | Merck Sharp & Dohme | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| WO2012087777A1 (en) | 2010-12-22 | 2012-06-28 | Merck Sharp & Dohme Corp. | Fused heterocyclic indane carboxamide cgrp receptor antagonists |
| EP2654423B1 (en) | 2010-12-22 | 2016-12-07 | Merck Sharp & Dohme Corp. | Fused heterocyclic azaindane carboxamide cgrp receptor antagonists |
| WO2012122279A1 (en) | 2011-03-08 | 2012-09-13 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| WO2012129013A1 (en) | 2011-03-18 | 2012-09-27 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
| EP2753640B1 (en) | 2011-09-08 | 2016-03-09 | Codexis, Inc. | Biocatalysts and methods for the synthesis of substituted lactams |
| WO2013138418A2 (en) | 2012-03-14 | 2013-09-19 | Merck Sharp & Dohme Corp. | Process for making cgrp receptor antagonists |
| WO2013138413A1 (en) | 2012-03-14 | 2013-09-19 | Merck Sharp & Dohme Corp. | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| WO2013162769A1 (en) | 2012-04-25 | 2013-10-31 | Centric Research Institute | Sensitization composition and method of use |
| US9227972B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam CGRP receptor antagonists |
| WO2013169563A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Pyridine cgrp receptor antagonists |
| EP2846799B1 (en) | 2012-05-09 | 2017-11-15 | Merck Sharp & Dohme Corp. | Spirolactam cgrp receptor antagonists |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| MY196014A (en) | 2013-03-15 | 2023-03-06 | Tonix Pharmaceuticals Inc | Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride |
| WO2015038736A2 (en) | 2013-09-16 | 2015-03-19 | Merck Sharp & Dohme Corp. | Formulations for cgrp receptor antagonists |
| US20240180883A1 (en) | 2020-12-22 | 2024-06-06 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| EP3102188A4 (en) | 2014-02-05 | 2017-07-12 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| US10117836B2 (en) | 2014-02-05 | 2018-11-06 | Merck Sharp & Dohme Corp. | Tablet formulation for CGRP active compounds |
| CN106456662A (zh) | 2014-02-24 | 2017-02-22 | 奥利金制药公司 | 口服给药的戊聚糖多硫酸盐的组合物及其使用方法 |
| KR20170043597A (ko) | 2014-08-22 | 2017-04-21 | 클로비스 온콜로지 인코포레이티드 | 루카파립의 고 용량 강도 정제 |
| CN107427493A (zh) | 2015-01-23 | 2017-12-01 | 格吕伦塔尔有限公司 | 用于治疗肝功能受损和/或肾功能受损的受试者的疼痛的Cebranopadol |
| JP2018532728A (ja) | 2015-09-24 | 2018-11-08 | テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー | （持続性）外傷後頭痛の予防、治療および低減 |
| US20180092899A1 (en) | 2016-09-30 | 2018-04-05 | Merck Sharp & Dohme Corp. | Method of treating acute migraine with cgrp-active compound |
| JP7195262B2 (ja) | 2017-03-02 | 2022-12-23 | ベス イスラエル デアコネス メディカル センター インコーポレイティッド | カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法 |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| US20190135927A1 (en) | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
| US20200353088A1 (en) | 2017-11-06 | 2020-11-12 | Auckland Uniservices Limited | Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof |
| US20190374520A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20190374518A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| TW202019459A (zh) | 2018-07-05 | 2020-06-01 | 愛爾蘭商歐樂根製藥國際有限公司 | Cgrp拮抗劑及梭菌衍生物之組合療法 |
| TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| KR20210116560A (ko) | 2019-01-20 | 2021-09-27 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 편두통 돌발을 치료하기 위한 cgrp 길항제 |
| US20200383983A1 (en) | 2019-04-18 | 2020-12-10 | Allergan Sales, Llc | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| WO2021005494A1 (en) | 2019-07-05 | 2021-01-14 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders |
| EP4034156A4 (en) | 2019-09-25 | 2024-01-24 | Allergan Pharmaceuticals International Limited | COMBINATION THERAPY WITH CGRP ANTAGONISTS |
| BR112022008118A2 (pt) * | 2019-10-31 | 2022-07-19 | Scherer Technologies Llc R P | Cápsula de supositório |
| MX2023001071A (es) | 2020-07-29 | 2023-05-12 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| JP2024533756A (ja) | 2021-09-27 | 2024-09-12 | アラガン ファーマスーティカルズ インターナショナル リミテッド | アトゲパントを含む片頭痛の併用療法 |
| CA3244873A1 (en) | 2022-03-09 | 2023-09-14 | Allergan Pharmaceuticals International Limited | Preventive treatment for migraines |
| US20260130901A1 (en) | 2022-10-11 | 2026-05-14 | Allergan Pharmaceuticals International Limited | Cgrp receptor antagonist for the treatment of migraine |
-
2022
- 2022-09-27 JP JP2024519064A patent/JP2024533756A/ja active Pending
- 2022-09-27 WO PCT/US2022/077061 patent/WO2023049920A1/en not_active Ceased
- 2022-09-27 AU AU2022353124A patent/AU2022353124A1/en active Pending
- 2022-09-27 US US17/953,536 patent/US12350259B2/en active Active
- 2022-09-27 CA CA3234080A patent/CA3234080A1/en active Pending
- 2022-09-27 MX MX2024003952A patent/MX2024003952A/es unknown
- 2022-09-27 EP EP22793079.9A patent/EP4408418A1/en active Pending
-
2024
- 2024-10-11 US US18/913,492 patent/US20250032467A1/en active Pending
- 2024-10-11 US US18/913,072 patent/US12465598B2/en active Active
-
2025
- 2025-02-18 US US19/055,912 patent/US20250186412A1/en not_active Abandoned
- 2025-02-18 US US19/055,916 patent/US12622897B2/en active Active
- 2025-09-17 US US19/331,536 patent/US12661341B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024533756A (ja) | 2024-09-12 |
| US12622897B2 (en) | 2026-05-12 |
| US20230130736A1 (en) | 2023-04-27 |
| US20260014127A1 (en) | 2026-01-15 |
| EP4408418A1 (en) | 2024-08-07 |
| AU2022353124A1 (en) | 2024-04-11 |
| US20250186412A1 (en) | 2025-06-12 |
| US12465598B2 (en) | 2025-11-11 |
| US20250032467A1 (en) | 2025-01-30 |
| US20250032466A1 (en) | 2025-01-30 |
| CA3234080A1 (en) | 2023-03-30 |
| US12350259B2 (en) | 2025-07-08 |
| US20250186413A1 (en) | 2025-06-12 |
| WO2023049920A1 (en) | 2023-03-30 |
| US12661341B2 (en) | 2026-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001071A (es) | Tratamiento de la migraña. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MY200810A (en) | Pyrrolidine compounds | |
| MX2023002004A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| MX2022007915A (es) | Compuestos de benzopirazol y analogos de estos. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2020006599A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| MX2020013352A (es) | Tratamiento para migrañas. | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| EP4706761A3 (en) | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| MX2023005806A (es) | Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras). | |
| MX2020003427A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
| MX2024010644A (es) | Uso de iptacopan para el tratamiento de la nefritis lupica. | |
| MX2023013148A (es) | Iptacopan para el tratamiento del sindrome uremico hemolitico atipico. | |
| ZA201908087B (en) | Treatment for migraine | |
| WO2021231931A8 (en) | Methods of treating sars-cov-2 infections | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| PH12019550154B1 (en) | Azetidine derivative |